SCHEMBL1358987

SCHEMBL1358987

Cn1ccc2cc(-c3ccc[nH]c3=O)cc(C(C)(C)C)c21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.40
KDM4E B2RXH2 3/20 0.37
ALDH1A1 P00352 3/20 0.37
GAA P10253 1/20 0.37
CYP1A2 P05177 1/20 0.37
HPGD P15428 1/20 0.37
NPC1 O15118 2/20 0.34
RAB9A P51151 1/20 0.34
ATM Q13315 1/20 0.34
ERAP1 Q9NZ08 1/20 0.34
BRD4 O60885 5/20 0.34
CREBBP Q92793 2/20 0.33
TAF1 P21675 1/20 0.33
BRPF1 P55201 1/20 0.33
CECR2 Q9BXF3 1/20 0.33
BRD9 Q9H8M2 1/20 0.33
GBA1 P04062 1/20 0.32
KMT2A Q03164 2/20 0.31
IGF1R P08069 1/20 0.31
ABL1 P00519 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1359862 0.75 MCL1 (0.39) CYP3A4KDM4EALDH1A1GAACYP1A2
SCHEMBL1359429 0.74 CYP3A4 (0.36) CYP3A4KDM4EBRD4ABL1
SCHEMBL1360187 0.73 CYP3A4 (0.40) CYP3A4KDM4EALDH1A1GAACYP1A2
SCHEMBL19499088 0.70 KCNH2 (0.34) CYP3A4CYP1A2
SCHEMBL1542685 0.69 CYP3A4 (0.55) CYP3A4BRD4IGF1RABL1CDK4
SCHEMBL1543040 0.69 CYP3A4 (0.55) CYP3A4KDM4EALDH1A1GAACYP1A2
SCHEMBL1543223 0.69 CYP3A4 (0.47) CYP3A4KDM4EALDH1A1GAAKMT2A
SCHEMBL2128925 0.68 CYP3A4 (0.54) CYP3A4KDM4EALDH1A1GAANPC1
SCHEMBL2128598 0.68 CYP3A4 (0.54) CYP3A4ALDH1A1ABL1
SCHEMBL1359848 0.68 CYP3A4 (0.40) CYP3A4KDM4EALDH1A1GAACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8067442-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2011-11-29 US disclosed
EP-2334662-A1 PYRINE OR PYRAZINE DERIVATIVES FOR TREATING HCV F. Hoffmann-La Roche AG (CH) 2011-06-22 EP disclosed
US-20100081658-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS ROCHE PALO ALTO LLC 2010-04-01 US disclosed
WO-2010034671-A1 PYRINE OR PYRAZINE DERIVATIVES FOR TREATING HCV F. HOFFMANN-LA ROCHE AG (CH) 2010-04-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100081658-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS EIF2AK2, POLR2A, HCCS CYP3A4 713/4885KDM4E 2198/4885ALDH1A1 1038/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.